Zentiva
Private Company
Funding information not available
Overview
Zentiva is a major European generics and biosimilars company with a 530-year heritage, founded in its modern form in 2003. It operates four manufacturing sites, employs over 5,400 people, and markets over 265 product presentations, ensuring supply security for essential medicines. The company is privately held, recently transitioning from ownership by Advent International to GTCR, and is strategically expanding into biosimilars while actively advocating for sustainable pharmaceutical policies in the EU.
Technology Platform
Integrated generics and biosimilars development and manufacturing platform focused on formulation science, analytical chemistry, bioprocessing, and regulatory strategy to produce high-quality, affordable medicines.
Funding History
1Opportunities
Risk Factors
Competitive Landscape
Zentiva competes in the crowded European generics market against other large players like Teva, Sandoz (Novartis), and Stada, as well as numerous regional manufacturers. Its move into biosimilars pits it against established biosimilar developers such as Samsung Bioepis, Celltrion, and Biogen. Competitive differentiation is achieved through supply reliability, manufacturing quality, a broad portfolio, and pan-European commercial reach.